Sigfox Signs A Global Partnership With Skyhook To Improve Delivery of Geolocation Services
Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, has announced today its partnership with Skyhook, the leading independent provider of Wi-Fi, cellular, and hybrid positioning. The collaboration is set to improve the quality and performance of existing tracking services on the Sigfox network globally, while delivering enhanced customer experience at an accessible cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005469/en/
As part of its services, Skyhook offers Wi-Fi location solutions, which can be used on its own or as part of a larger hybrid positioning system. This software-based, power-efficient approach uses Wi-Fi, GPS/GNSS, and cellular signals to track location, and uses over 6 billion geolocated Wi-Fi access points, over 110 million geolocated cells, and 1.5 billion geolocated IP addresses for unmatched reliability and accuracy. Through its unique approach, Skyhook’s Precision Location solution is able to accurately locate connected devices anywhere in the world.
By integrating global coverage from Skyhook’s positioning services with Sigfox’s existing Atlas Wi-Fi service, companies will be able to locate their assets in indoor environments, where other positioning methods can fall short. Customers directly benefit from the integration of Skyhook services, removing the need for additional infrastructure, regardless of the size and quantity of assets.
Atlas Wi-Fi, Sigfox’s geolocation service for massive IoT applications is specifically optimized to support global supply chain and logistics applications and combines two technologies and data sources - the Sigfox network and Wi-Fi infrastructure. Accordingly, Sigfox can provide one single location service in all types of geographic environments, without GPS.
Additionally, as Wi-Fi-based location tracking consumes less battery than using GPS, this new partnership will help extend the service life of IoT tracking solutions, thus reducing maintenance costs.
“Skyhook is proud to partner with Sigfox to ensure accurate location information is available regardless of whether an asset is inside a warehouse, outside in the lot or in transit. Integrating Skyhook’s technology into Sigfox’s global location platform is an important next step as Sigfox maintains its position as a recognized global leader in the IoT space,” said Craig Waggy, CEO of Skyhook.
“This partnership with Skyhook will help our clients gain better visibility of their supply chains, and ultimately provide a better service to their end customers. Understanding the exact location of assets globally without the additional costs associated with new infrastructure will no doubt drive business efficiencies. We see major traction around postal, retail and automotive use cases and Skyhook will help us provide the right quality of services for these key customers,” added Benjamin Mazet, Asset Tracking Director at Sigfox.
******
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Skyhook
Skyhook is the worldwide independent leader in location technology, operating the world's largest independent location network, consisting of over 6 billion geolocated Wi-Fi access points, over 110 million geolocated cells, and 1.5 billion geolocated IP addresses. Skyhook processes tens of billions of location transactions, serving devices, apps, wearables, brands and advertising platforms with precise and accurate location data and intelligence. Skyhook, through its parent company Skyhook Holding, Inc., operates as a wholly owned subsidiary of Liberty Broadband Corporation. To learn more visit www.skyhook.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005469/en/
Contact information
Press Contacts
S
igfox
Antoine Mège, Corporate Communications
antoine.mege@sigfox.com
Skyhook
Isolde Decker-Lucke, Marketing Manager
idecker-lucke@skyhook.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 11:30:00 EEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 08:00:00 EEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 19:27:00 EEST | Press release
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r
Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 19:00:00 EEST | Press release
Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with
Methane Electrolysis Can Decarbonize LNG/LPG Imports and Achieve EU’s Climate Targets18.8.2022 15:00:00 EEST | Press release
To become independent of Russian natural gas imports by 2027, the European Union is increasing near-term imports of US or Azerbaijan liquefied natural gas (LNG) or liquefied petroleum gas (LPG). The main element of LNG, methane, is the second leading greenhouse gas contributing to climate change. Environmental organizations warn that long-term supply contracts for the fossil LNG will undermine the European Green Deal. The German company Graforce has developed a methane electrolysis technology (plasmalysis) that uses LNG or LPG to produce hydrogen and solid carbon for dioxide-free energy generation. Compared to water electrolysis, plasmalysis requires only one fifth the energy to produce the same amount of hydrogen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005013/en/ Graforce has developed methane electrolysis plants. Errected at LNG terminals or other decentralized locations, they can decarbonize energy supply, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom